Download PDF
Digestive Disease Interventions 2022; 06(03): 209-218
DOI: 10.1055/s-0042-1751238
Review Article

Update on Cholangiocarcinoma

David Irwin 
1   Division of Diagnostic Imaging, Department of Interventional Radiology, The University of Texas, MD Anderson Cancer Center, Houston, Texas
› Author Affiliations Funding None.
› Further Information
Also available at
    Permissions and Reprints

Abstract

Cholangiocarcinoma remains a challenge both in terms of diagnosis and treatment. Due to the lack of a useful screening test and often clinically silent early course, disease stage is often advanced at the time of diagnosis. Surgical resection remains the only potentially curative treatment option and recurrence rates are high; however, liver transplantation has recently resulted in promising outcomes in certain groups of patients with intrahepatic and perihilar cholangiocarcinoma. For patients in whom surgery is not an option, chemotherapy with gemcitabine and cisplatin is the first-line treatment. An array of locoregional management options exists, which includes transarterial embolization, hepatic arterial chemotherapy infusion, ablation, and radiation therapy. High-quality data from randomized controlled trials for these treatments remains limited, however, and additional study is needed.

Keywords

cholangiocarcinoma - embolization - ablation


Publication History

Received: 18 March 2022

Accepted: 25 May 2022

Article published online:
11 July 2022

© 2022. Thieme. All rights reserved.

Thieme Medical Publishers, Inc.
333 Seventh Avenue, 18th Floor, New York, NY 10001, USA

 

  • References

  • 1 Fitzmaurice C, Dicker D, Pain A. et al; Global Burden of Disease Cancer Collaboration. The global burden of cancer 2013. JAMA Oncol 2015; 1 (04) 505-527
    CrossrefPubMedGoogle Scholar
  • 2 Blechacz B, Komuta M, Roskams T, Gores GJ. Clinical diagnosis and staging of cholangiocarcinoma. Nat Rev Gastroenterol Hepatol 2011; 8 (09) 512-522
    CrossrefPubMedGoogle Scholar
  • 3 Palmer WC, Patel T. Are common factors involved in the pathogenesis of primary liver cancers? A meta-analysis of risk factors for intrahepatic cholangiocarcinoma. J Hepatol 2012; 57 (01) 69-76
    CrossrefPubMedGoogle Scholar
  • 4 Ohta T, Nagakawa T, Ueda N. et al. Mucosal dysplasia of the liver and the intraductal variant of peripheral cholangiocarcinoma in hepatolithiasis. Cancer 1991; 68 (10) 2217-2223
    CrossrefPubMedGoogle Scholar
  • 5 Saha SK, Zhu AX, Fuchs CS, Brooks GA. Forty-year trends in cholangiocarcinoma incidence in the U.S.: intrahepatic disease on the rise. Oncologist 2016; 21 (05) 594-599
    CrossrefPubMedGoogle Scholar
  • 6 Welzel TM, Graubard BI, El-Serag HB. et al. Risk factors for intrahepatic and extrahepatic cholangiocarcinoma in the United States: a population-based case-control study. Clin Gastroenterol Hepatol 2007; 5 (10) 1221-1228
    CrossrefPubMedGoogle Scholar
  • 7 Tyson GL, El-Serag HB. Risk factors for cholangiocarcinoma. Hepatology 2011; 54 (01) 173-184
    CrossrefPubMedGoogle Scholar
  • 8 Olnes MJ, Erlich R. A review and update on cholangiocarcinoma. Oncology 2004; 66 (03) 167-179
    CrossrefPubMedGoogle Scholar
  • 9 Deoliveira ML, Schulick RD, Nimura Y. et al. New staging system and a registry for perihilar cholangiocarcinoma. Hepatology 2011; 53 (04) 1363-1371
    CrossrefPubMedGoogle Scholar
  • 10 Banales JM, Cardinale V, Carpino G. et al. Expert consensus document: cholangiocarcinoma: current knowledge and future perspectives consensus statement from the European Network for the Study of Cholangiocarcinoma (ENS-CCA). Nat Rev Gastroenterol Hepatol 2016; 13 (05) 261-280
    CrossrefPubMedGoogle Scholar
  • 11 El Rassi ZE, Partensky C, Scoazec JY, Henry L, Lombard-Bohas C, Maddern G. Peripheral cholangiocarcinoma: presentation, diagnosis, pathology and management. Eur J Surg Oncol 1999; 25 (04) 375-380
    CrossrefPubMedGoogle Scholar
  • 12 Alvaro D, Bragazzi MC, Benedetti A. et al; AISF “Cholangiocarcinoma” committee. Cholangiocarcinoma in Italy: a national survey on clinical characteristics, diagnostic modalities and treatment. Results from the “Cholangiocarcinoma” committee of the Italian Association for the Study of Liver disease. Dig Liver Dis 2011; 43 (01) 60-65
    CrossrefPubMedGoogle Scholar
  • 13 Cho MS, Kim SH, Park SW. et al. Surgical outcomes and predicting factors of curative resection in patients with hilar cholangiocarcinoma: 10-year single-institution experience. J Gastrointest Surg 2012; 16 (09) 1672-1679
    CrossrefPubMedGoogle Scholar
  • 14 de Jong MC, Marques H, Clary BM. et al. The impact of portal vein resection on outcomes for hilar cholangiocarcinoma: a multi-institutional analysis of 305 cases. Cancer 2012; 118 (19) 4737-4747
    CrossrefPubMedGoogle Scholar
  • 15 Lidsky ME, Jarnagin WR. Surgical management of hilar cholangiocarcinoma at Memorial Sloan Kettering Cancer Center. Ann Gastroenterol Surg 2018; 2 (04) 304-312
    CrossrefPubMedGoogle Scholar
  • 16 Mansour JC, Aloia TA, Crane CH, Heimbach JK, Nagino M, Vauthey JN. Hilar cholangiocarcinoma: expert consensus statement. HPB (Oxford) 2015; 17 (08) 691-699
    CrossrefPubMedGoogle Scholar
  • 17 Banales JM, Marin JJG, Lamarca A. et al. Cholangiocarcinoma 2020: the next horizon in mechanisms and management. Nat Rev Gastroenterol Hepatol 2020; 17 (09) 557-588
    CrossrefPubMedGoogle Scholar
  • 18 Blechacz B. Cholangiocarcinoma: current knowledge and new developments. Gut Liver 2017; 11 (01) 13-26
    CrossrefPubMedGoogle Scholar
  • 19 Primrose JN, Fox RP, Palmer DH. et al; BILCAP Study Group. Capecitabine compared with observation in resected biliary tract cancer (BILCAP): a randomised, controlled, multicentre, phase 3 study. Lancet Oncol 2019; 20 (05) 663-673
    CrossrefPubMedGoogle Scholar
  • 20 Chun YS, Pawlik TM, Vauthey JN. 8th Edition of the AJCC Cancer Staging Manual: pancreas and hepatobiliary cancers. Ann Surg Oncol 2018; 25 (04) 845-847
    CrossrefPubMedGoogle Scholar
  • 21 Weber SM, Ribero D, O'Reilly EM, Kokudo N, Miyazaki M, Pawlik TM. Intrahepatic cholangiocarcinoma: expert consensus statement. HPB (Oxford) 2015; 17 (08) 669-680
    CrossrefPubMedGoogle Scholar
  • 22 Nuzzo G, Giuliante F, Ardito F. et al; Italian Chapter of the International Hepato-Pancreato-Biliary Association. Improvement in perioperative and long-term outcome after surgical treatment of hilar cholangiocarcinoma: results of an Italian multicenter analysis of 440 patients. Arch Surg 2012; 147 (01) 26-34
    CrossrefPubMedGoogle Scholar
  • 23 Khan AS, Garcia-Aroz S, Ansari MA. et al. Assessment and optimization of liver volume before major hepatic resection: current guidelines and a narrative review. Int J Surg 2018; 52: 74-81
    CrossrefPubMedGoogle Scholar
  • 24 Abdalla EK. Portal vein embolization (prior to major hepatectomy) effects on regeneration, resectability, and outcome. J Surg Oncol 2010; 102 (08) 960-967
    CrossrefPubMedGoogle Scholar
  • 25 Shindoh J, Vauthey JN, Zimmitti G. et al. Analysis of the efficacy of portal vein embolization for patients with extensive liver malignancy and very low future liver remnant volume, including a comparison with the associating liver partition with portal vein ligation for staged hepatectomy approach. J Am Coll Surg 2013; 217 (01) 126-133 , discussion 133–134
    CrossrefPubMedGoogle Scholar
  • 26 Abulkhir A, Limongelli P, Healey AJ. et al. Preoperative portal vein embolization for major liver resection: a meta-analysis. Ann Surg 2008; 247 (01) 49-57
    CrossrefPubMedGoogle Scholar
  • 27 Gabr A, Abouchaleh N, Ali R. et al. Outcomes of surgical resection after radioembolization for hepatocellular carcinoma. J Vasc Interv Radiol 2018; 29 (11) 1502-1510.e1
    CrossrefPubMedGoogle Scholar
  • 28 Teo JY, Allen Jr JC, Ng DC. et al. A systematic review of contralateral liver lobe hypertrophy after unilobar selective internal radiation therapy with Y90. HPB (Oxford) 2016; 18 (01) 7-12
    CrossrefPubMedGoogle Scholar
  • 29 Lee DD, Croome KP, Musto KR. et al. Liver transplantation for intrahepatic cholangiocarcinoma. Liver Transpl 2018; 24 (05) 634-644
    CrossrefPubMedGoogle Scholar
  • 30 Sapisochin G, de Lope CR, Gastaca M. et al. Intrahepatic cholangiocarcinoma or mixed hepatocellular-cholangiocarcinoma in patients undergoing liver transplantation: a Spanish matched cohort multicenter study. Ann Surg 2014; 259 (05) 944-952
    CrossrefPubMedGoogle Scholar
  • 31 Sapisochin G, Facciuto M, Rubbia-Brandt L. et al; iCCA International Consortium. Liver transplantation for “very early” intrahepatic cholangiocarcinoma: international retrospective study supporting a prospective assessment. Hepatology 2016; 64 (04) 1178-1188
    CrossrefPubMedGoogle Scholar
  • 32 Jarnagin WR, Fong Y, DeMatteo RP. et al. Staging, resectability, and outcome in 225 patients with hilar cholangiocarcinoma. Ann Surg 2001; 234 (04) 507-517 , discussion 517–519
    CrossrefPubMedGoogle Scholar
  • 33 Kobayashi A, Miwa S, Nakata T, Miyagawa S. Disease recurrence patterns after R0 resection of hilar cholangiocarcinoma. Br J Surg 2010; 97 (01) 56-64
    CrossrefPubMedGoogle Scholar
  • 34 Abbas S, Sandroussi C. Systematic review and meta-analysis of the role of vascular resection in the treatment of hilar cholangiocarcinoma. HPB (Oxford) 2013; 15 (07) 492-503
    CrossrefPubMedGoogle Scholar
  • 35 Darwish Murad S, Kim WR, Harnois DM. et al. Efficacy of neoadjuvant chemoradiation, followed by liver transplantation, for perihilar cholangiocarcinoma at 12 US centers. Gastroenterology 2012; 143 (01) 88-98.e3 , quiz e14
    CrossrefPubMedGoogle Scholar
  • 36 Rea DJ, Heimbach JK, Rosen CB. et al. Liver transplantation with neoadjuvant chemoradiation is more effective than resection for hilar cholangiocarcinoma. Ann Surg 2005; 242 (03) 451-458 , discussion 458–461
    CrossrefPubMedGoogle Scholar
  • 37 Sudan D, DeRoover A, Chinnakotla S. et al. Radiochemotherapy and transplantation allow long-term survival for nonresectable hilar cholangiocarcinoma. Am J Transplant 2002; 2 (08) 774-779
    CrossrefPubMedGoogle Scholar
  • 38 Kwon HJ, Kim SG, Chun JM, Lee WK, Hwang YJ. Prognostic factors in patients with middle and distal bile duct cancers. World J Gastroenterol 2014; 20 (21) 6658-6665
    CrossrefPubMedGoogle Scholar
  • 39 Dickson PV, Behrman SW. Distal cholangiocarcinoma. Surg Clin North Am 2014; 94 (02) 325-342
    CrossrefPubMedGoogle Scholar
  • 40 Valle J, Wasan H, Palmer DH. et al; ABC-02 Trial Investigators. Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer. N Engl J Med 2010; 362 (14) 1273-1281
    CrossrefPubMedGoogle Scholar
  • 41 Kodali S, Shetty A, Shekhar S, Victor DW, Ghobrial RM. Management of intrahepatic cholangiocarcinoma. J Clin Med 2021; 10 (11) 2368
    CrossrefPubMedGoogle Scholar
  • 42 Tao R, Krishnan S, Bhosale PR. et al. Ablative radiotherapy doses lead to a substantial prolongation of survival in patients with inoperable intrahepatic cholangiocarcinoma: a retrospective dose response Analysis. J Clin Oncol 2016; 34 (03) 219-226
    CrossrefPubMedGoogle Scholar
  • 43 Patel T. Cholangiocarcinoma – controversies and challenges. Nat Rev Gastroenterol Hepatol 2011; 8 (04) 189-200
    CrossrefPubMedGoogle Scholar
  • 44 Ackerman NB, Lien WM, Kondi ES, Silverman NA. The blood supply of experimental liver metastases. I. The distribution of hepatic artery and portal vein blood to “small” and “large” tumors. Surgery 1969; 66 (06) 1067-1072
    PubMedGoogle Scholar
  • 45 Archer SG, Gray BN. Vascularization of small liver metastases. Br J Surg 1989; 76 (06) 545-548
    CrossrefPubMedGoogle Scholar
  • 46 Hyder O, Marsh JW, Salem R. et al. Intra-arterial therapy for advanced intrahepatic cholangiocarcinoma: a multi-institutional analysis. Ann Surg Oncol 2013; 20 (12) 3779-3786
    CrossrefPubMedGoogle Scholar
  • 47 Ray Jr CE, Edwards A, Smith MT. et al. Metaanalysis of survival, complications, and imaging response following chemotherapy-based transarterial therapy in patients with unresectable intrahepatic cholangiocarcinoma. J Vasc Interv Radiol 2013; 24 (08) 1218-1226
    CrossrefPubMedGoogle Scholar
  • 48 Burger I, Hong K, Schulick R. et al. Transcatheter arterial chemoembolization in unresectable cholangiocarcinoma: initial experience in a single institution. J Vasc Interv Radiol 2005; 16 (03) 353-361
    CrossrefPubMedGoogle Scholar
  • 49 Kennedy A, Coldwell D, Sangro B, Wasan H, Salem R. Radioembolization for the treatment of liver tumors general principles. Am J Clin Oncol 2012; 35 (01) 91-99
    CrossrefPubMedGoogle Scholar
  • 50 Salem R, Lewandowski RJ, Atassi B. et al. Treatment of unresectable hepatocellular carcinoma with use of 90Y microspheres (TheraSphere): safety, tumor response, and survival. J Vasc Interv Radiol 2005; 16 (12) 1627-1639
    CrossrefPubMedGoogle Scholar
  • 51 Murthy R, Nunez R, Szklaruk J. et al. Yttrium-90 microsphere therapy for hepatic malignancy: devices, indications, technical considerations, and potential complications. Radiographics 2005; 25 (Suppl. 01) S41-S55
    CrossrefPubMedGoogle Scholar
  • 52 Kennedy AS, Coldwell D, Nutting C. et al. Resin 90Y-microsphere brachytherapy for unresectable colorectal liver metastases: modern USA experience. Int J Radiat Oncol Biol Phys 2006; 65 (02) 412-425
    CrossrefPubMedGoogle Scholar
  • 53 Young JY, Rhee TK, Atassi B. et al. Radiation dose limits and liver toxicities resulting from multiple yttrium-90 radioembolization treatments for hepatocellular carcinoma. J Vasc Interv Radiol 2007; 18 (11) 1375-1382
    CrossrefPubMedGoogle Scholar
  • 54 Sangro B, Gil-Alzugaray B, Rodriguez J. et al. Liver disease induced by radioembolization of liver tumors: description and possible risk factors. Cancer 2008; 112 (07) 1538-1546
    CrossrefPubMedGoogle Scholar
  • 55 Kennedy AS, McNeillie P, Dezarn WA. et al. Treatment parameters and outcome in 680 treatments of internal radiation with resin 90Y-microspheres for unresectable hepatic tumors. Int J Radiat Oncol Biol Phys 2009; 74 (05) 1494-1500
    CrossrefPubMedGoogle Scholar
  • 56 Murthy R, Brown DB, Salem R. et al. Gastrointestinal complications associated with hepatic arterial yttrium-90 microsphere therapy. J Vasc Interv Radiol 2007; 18 (04) 553-561 , quiz 562
    CrossrefPubMedGoogle Scholar
  • 57 Mallach S, Ramp U, Erhardt A, Schmitt M, Häussinger D. An uncommon cause of gastro-duodenal ulceration. World J Gastroenterol 2008; 14 (16) 2593-2595
    CrossrefPubMedGoogle Scholar
  • 58 Leung TW, Lau WY, Ho SK. et al. Radiation pneumonitis after selective internal radiation treatment with intraarterial 90yttrium-microspheres for inoperable hepatic tumors. Int J Radiat Oncol Biol Phys 1995; 33 (04) 919-924
    CrossrefPubMedGoogle Scholar
  • 59 Salem R, Parikh P, Atassi B. et al. Incidence of radiation pneumonitis after hepatic intra-arterial radiotherapy with yttrium-90 microspheres assuming uniform lung distribution. Am J Clin Oncol 2008; 31 (05) 431-438
    CrossrefPubMedGoogle Scholar
  • 60 Ibrahim SM, Mulcahy MF, Lewandowski RJ. et al. Treatment of unresectable cholangiocarcinoma using yttrium-90 microspheres: results from a pilot study. Cancer 2008; 113 (08) 2119-2128
    CrossrefPubMedGoogle Scholar
  • 61 Mouli S, Memon K, Baker T. et al. Yttrium-90 radioembolization for intrahepatic cholangiocarcinoma: safety, response, and survival analysis. J Vasc Interv Radiol 2013; 24 (08) 1227-1234
    CrossrefPubMedGoogle Scholar
  • 62 Al-Adra DP, Gill RS, Axford SJ, Shi X, Kneteman N, Liau SS. Treatment of unresectable intrahepatic cholangiocarcinoma with yttrium-90 radioembolization: a systematic review and pooled analysis. Eur J Surg Oncol 2015; 41 (01) 120-127
    CrossrefPubMedGoogle Scholar
  • 63 Zhen Y, Liu B, Chang Z, Ren H, Liu Z, Zheng J. A pooled analysis of transarterial radioembolization with yttrium-90 microspheres for the treatment of unresectable intrahepatic cholangiocarcinoma. OncoTargets Ther 2019; 12: 4489-4498
    CrossrefPubMedGoogle Scholar
  • 64 Mosconi C, Solaini L, Vara G. et al. Transarterial chemoembolization and radioembolization for unresectable intrahepatic cholangiocarcinoma - a systemic review and meta-analysis. Cardiovasc Intervent Radiol 2021; 44 (05) 728-738
    CrossrefPubMedGoogle Scholar
  • 65 Konstantinidis IT, Groot Koerkamp B, Do RK. et al. Unresectable intrahepatic cholangiocarcinoma: Systemic plus hepatic arterial infusion chemotherapy is associated with longer survival in comparison with systemic chemotherapy alone. Cancer 2016; 122 (05) 758-765
    CrossrefPubMedGoogle Scholar
  • 66 Boehm LM, Jayakrishnan TT, Miura JT. et al. Comparative effectiveness of hepatic artery based therapies for unresectable intrahepatic cholangiocarcinoma. J Surg Oncol 2015; 111 (02) 213-220
    CrossrefPubMedGoogle Scholar
  • 67 Hong K, Georgiades C. Radiofrequency ablation: mechanism of action and devices. J Vasc Interv Radiol 2010; 21 (8, Suppl): S179-S186
    CrossrefPubMedGoogle Scholar
  • 68 Lubner MG, Brace CL, Hinshaw JL, Lee Jr FT. Microwave tumor ablation: mechanism of action, clinical results, and devices. J Vasc Interv Radiol 2010; 21 (8, Suppl): S192-S203
    CrossrefPubMedGoogle Scholar
  • 69 Slakey DP. Radiofrequency ablation of recurrent cholangiocarcinoma. Am Surg 2002; 68 (04) 395-397
    CrossrefPubMedGoogle Scholar
  • 70 Han K, Ko HK, Kim KW, Won HJ, Shin YM, Kim PN. Radiofrequency ablation in the treatment of unresectable intrahepatic cholangiocarcinoma: systematic review and meta-analysis. J Vasc Interv Radiol 2015; 26 (07) 943-948
    CrossrefPubMedGoogle Scholar
  • 71 Haidu M, Dobrozemsky G, Schullian P. et al. Stereotactic radiofrequency ablation of unresectable intrahepatic cholangiocarcinomas: a retrospective study. Cardiovasc Intervent Radiol 2012; 35 (05) 1074-1082
    CrossrefPubMedGoogle Scholar
  • 72 Yu MA, Liang P, Yu XL. et al. Sonography-guided percutaneous microwave ablation of intrahepatic primary cholangiocarcinoma. Eur J Radiol 2011; 80 (02) 548-552
    CrossrefPubMedGoogle Scholar
  • 73 Zhang K, Yu J, Yu X. et al. Clinical and survival outcomes of percutaneous microwave ablation for intrahepatic cholangiocarcinoma. Int J Hyperthermia 2018; 34 (03) 292-297
    CrossrefPubMedGoogle Scholar
  • 74 Yousaf A, Kim JU, Eliahoo J, Taylor-Robinson SD, Khan SA. Ablative therapy for unresectable intrahepatic cholangiocarcinoma: a systematic review and meta-analysis. J Clin Exp Hepatol 2019; 9 (06) 740-748
    CrossrefPubMedGoogle Scholar
  • 75 Peng ZW, Chen MS, Liang HH. et al. A case-control study comparing percutaneous radiofrequency ablation alone or combined with transcatheter arterial chemoembolization for hepatocellular carcinoma. Eur J Surg Oncol 2010; 36 (03) 257-263
    CrossrefPubMedGoogle Scholar
  • 76 Yang GW, Zhao Q, Qian S. et al. Percutaneous microwave ablation combined with simultaneous transarterial chemoembolization for the treatment of advanced intrahepatic cholangiocarcinoma. OncoTargets Ther 2015; 8: 1245-1250
    CrossrefPubMedGoogle Scholar
  • 77 Kim YI, Park JW, Kim BH. et al. Outcomes of concurrent chemoradiotherapy versus chemotherapy alone for advanced-stage unresectable intrahepatic cholangiocarcinoma. Radiat Oncol 2013; 8: 292
    CrossrefPubMedGoogle Scholar
  • 78 Hung SP, Huang BS, Hsieh CE. et al. Clinical outcomes of patients with unresectable cholangiocarcinoma treated with proton beam therapy. Am J Clin Oncol 2020; 43 (03) 180-186
    CrossrefPubMedGoogle Scholar
  • 79 Hong TS, Wo JY, Yeap BY. et al. Multi-institutional phase II study of high-dose hypofractionated proton beam therapy in patients with localized, unresectable hepatocellular carcinoma and intrahepatic cholangiocarcinoma. J Clin Oncol 2016; 34 (05) 460-468
    CrossrefPubMedGoogle Scholar
  • 80 Chen P, Yang T, Shi P, Shen J, Feng Q, Su J. Benefits and safety of photodynamic therapy in patients with hilar cholangiocarcinoma: a meta-analysis. Photodiagn Photodyn Ther 2022; 37: 102712
    CrossrefPubMedGoogle Scholar
  • 81 Mönkemüller K, Popa D, Wilcox CM. Endoscopic treatment options for cholangiocarcinomas. Expert Rev Anticancer Ther 2014; 14 (04) 407-418
    CrossrefPubMedGoogle Scholar
  • 82 Moole H, Tathireddy H, Dharmapuri S. et al. Success of photodynamic therapy in palliating patients with nonresectable cholangiocarcinoma: a systematic review and meta-analysis. World J Gastroenterol 2017; 23 (07) 1278-1288
    CrossrefPubMedGoogle Scholar